Half Yearly Report

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience publishes its interim results for the six months to 30 June 2013

Oxford Pharmascience Group Plc is pleased to announce its unaudited interim results for the six months to 30 June 2013.

DownloadThe full interim results are available to view and download via the following link:

http://www.rns-pdf.londonstockexchange.com/rns/2445O_-2013-9-17.pdf

Chairman's Statement

The first half of 2013 has seen continued progress in the growth of the business and evolution of Oxford Pharmascience into a drug re-development company with an exciting pipeline of innovative medicines with huge commercial potential.

The Group's strategy is now firmly established on re-developing already approved oral prescription and OTC products to address unmet patient needs with significant commercial potential. Focusing on off-patent drugs that have been approved and been in extensive use for a long time reduces both development and commercial risk and results in a simplified drug development regulatory pathway. This in turn allows for less expensive development programmes and faster access to market.

Having spent its initial years establishing its core technology platforms the group has refocused its activities on applying these technologies to developing improved formulations of existing drugs in the large pharmaceutical sectors of pain relief and cardiovascular treatments, specifically on NSAIDs and Statins. These are two of the largest drug categories in the world with combined sales of c $24bn and are dominated by off patent drugs. Re-developing these drugs to reduce side effects and improve compliance for the majority of patients taking these medicines is a compelling strategy and the group is well placed to deliver exciting new products in this manner.

The raising of a further £5m in March of this year has allowed the Group to push on with the development of taste masked ibuprofen products and its programme for new versions of the blockbuster drugs atorvastatin and simvastatin. In May we announced positive animal studies that showed the OXPzero™ technology could have the potential to reduce the risk for patients taking NSAIDs on a long term basis of developing ulcers and other serious gastric conditions. The Company has already begun to put in place a programme to develop ibuprofen tablets to reduce this gastric risk using the OXPzero™ ibuprofen salt it has already developed.

In addition we have recently strengthened our internal team and now have a strong scientific advisory board that has started providing guidance on the clinical programmes to bring these products to market.

Preparations to initiate this work are on-going and clinical programmes for ibuprofen and statins will begin in 2014. Full details will be published shortly along with key milestones to allow shareholders to monitor the progress of the programmes.

The future is incredibly exciting and existing business growth shows a glimpse of what the Group can do once its products reach market. Our calcium product continues to grow from strength to strength. Group sales for the first half of 2013 were £501,000, 47% higher than the same period last year and 7.5% higher than the whole of 2012. Strong growth in sales is expected to continue in the second half of 2013.

This is just the start of what the future has to offer for Oxford Pharmascience and I am delighted at the speed of transition the group has shown in the first 6 months of 2013

David Norwood

Chairman

18 September 2013 

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

N+1 Singer

Shaun Dobson/Jenny Wyllie +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.